Stocks and Investing Stocks and Investing
Wed, February 8, 2023

Mayank Mamtani Maintained (ARWR) at Strong Buy with Decreased Target to $55 on, Feb 8th, 2023


Published on 2024-10-28 01:28:14 - WOPRAI, Mayank Mamtani
  Print publication without navigation


Mayank Mamtani of B. Riley Securities, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy with Decreased Target from $59 to $55 on, Feb 8th, 2023.

Mayank has made no other calls on ARWR in the last 4 months.



There are 7 other peers that have a rating on ARWR. Out of the 7 peers that are also analyzing ARWR, 2 agree with Mayank's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Galler of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Tuesday, November 29th, 2022
  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Decreased Target to $31 on, Tuesday, November 29th, 2022


These are the ratings of the 5 analyists that currently disagree with Mayank


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $52 on, Tuesday, February 7th, 2023
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $58 on, Tuesday, February 7th, 2023
  • Luca Issi of "RBC Capital" Maintained at Buy with Decreased Target to $77 on, Tuesday, February 7th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $90 on, Tuesday, December 6th, 2022
  • Maury Raycroft of "Jefferies" Maintained at Strong Buy with Decreased Target to $75 on, Tuesday, November 29th, 2022
Contributing Sources